February 26, 2020 / 10:37 PM / in a month

BRIEF-G1 Therapeutics Says Rintodestrant Combination Trial With Palbociclib Expected To Initiate In Q2

Feb 26 (Reuters) - G1 Therapeutics Inc:

* G1 THERAPEUTICS INC - RINTODESTRANT COMBINATION TRIAL WITH PALBOCICLIB EXPECTED TO INITIATE IN 2Q20

* G1 THERAPEUTICS INC - NEW DRUG APPLICATION SUBMISSION FOR TRILACICLIB IN SMALL CELL LUNG CANCER ON TRACK FOR Q2 2020

* G1 THERAPEUTICS INC - EXPECTS TO END 2020 WITH $110MLN - $130 MILLION IN CASH & CASH EQUIVALENTS

* G1 THERAPEUTICS - EXPECTS YEAR-END 2019 CASH & CASH EQUIVALENTS OF $269.2 MILLION TO BE SUFFICIENT TO FUND ITS OPERATING EXPENSES & CAPEX INTO H2 2021

* G1 THERAPEUTICS INC QTRLY LOSS PER SHARE $0.94 Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below